Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576555 | 1.00 | CAPN1 (0.52) | CAPN1HDAC1HDAC8MEN1KMT2A | |
| SCHEMBL8256601 | 0.84 | CACNA1B (0.50) | CAPN1HDAC1MEN1KMT2ACTSS | |
| SCHEMBL560137 | 0.84 | CACNA1B (0.50) | CAPN1HDAC1MEN1KMT2ACTSS | |
| SCHEMBL560138 | 0.84 | CACNA1B (0.50) | CAPN1HDAC1MEN1KMT2ACTSS | |
| SCHEMBL3574991 | 0.81 | SMN1; SMN2 (0.41) | POLBGAABCHESMN1; SMN2 | |
| SCHEMBL3571893 | 0.81 | SMN1; SMN2 (0.41) | POLBGAABCHESMN1; SMN2 | |
| SCHEMBL3581970 | 0.81 | DRD2 (0.38) | CAPN1HDAC1MEN1KMT2ANPSR1 | |
| SCHEMBL3581972 | 0.81 | DRD2 (0.38) | CAPN1HDAC1MEN1KMT2ANPSR1 | |
| SCHEMBL3566178 | 0.80 | NPR3 (0.43) | HDAC1HDAC8MEN1KMT2ANPSR1 | |
| SCHEMBL3566181 | 0.80 | NPR3 (0.43) | HDAC1HDAC8MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
| EP-2079742-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008050078-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CAPN1 3109/4885HDAC1 1883/4885HDAC8 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.